Jinxin oral liquid inhibits human respiratory syncytial virus-induced excessive inflammation associated with blockade of the NLRP3/ASC/Caspase-1 pathway

Cunsi Shen(Nanjing University of Chinese Medicine), Jinjun Shan(Nanjing University of Chinese Medicine), Kang An(Nanjing University of Chinese Medicine), Qigang Dai(Jiangsu Provincial Center for Disease Control and Prevention), Zhengguang Zhang(Nanjing University of Chinese Medicine), Jianjian Ji(Nanjing University of Chinese Medicine), Tong Xie(Nanjing University of Chinese Medicine), Jianya Xu(Nanjing University of Chinese Medicine), Jing Yan(Jiangxi Pingxiang People's Hospital), Shouchuan Wang(Nanjing University of Chinese Medicine)
Biomedicine & Pharmacotherapy
May 7, 2018
Cited by 25


Related Papers